Emergent BioSolutions Inc. | Capital Stewardship Misalignment at Emergent BioSolutions Inc.

Status
Omitted
Previous AGM date
Resolution details
Company ticker
EBS
Lead filer
Individual
Resolution ask
Adopt or amend a policy
ESG theme
  • Governance
ESG sub-theme
  • Remuneration or pay
Type of vote
Shareholder proposal
Filer type
Shareholder
Company HQ country
United States
Resolved clause
RESOLVED: Compensation & Governance Reform That shareholders recommend the Board of Directors adopt policies mandating all future equity incentive compensation programs for Named Executive Officers (NEOs) and NonEmployee Directors (NEDs) be based on clearly defined, objective, market-based performance metrics. RTSR Mandate (All Insiders): At least 50% of long-term equity grants for NEOs and NEDs must be based on Relative Total Shareholder Return versus a clear, disclosed peer group over a multi-year timeframe. EPS Adjustment (NEOs Only): EPS targets for compensation plans must be calculated on a fully diluted share count, assuming completion of all authorized repurchases at the lower of the current stock price or VWAP during the performance period.
Supporting statement
Final Shareholder Proposal Resolution & Supporting Statement Capital Stewardship Misalignment This misalignment is evidenced by a sustained failure to fully execute the authorized $50 million stock buyback program. Following its March 27, 2025 announcement, the stock traded in the deeply discounted $4–$6 range until mid-May, presenting an unprecedented opportunity to retire shares at a compelling valuation. Given the Company’s Average Daily Trading Volume in the period, the legal limit (Rule 10b-18) permitted the purchase of approximately 275,000 shares per day, translating to a capacity of over 5.7 million shares per month. Even accounting for standard quarterly blackout periods, the Company failed to execute aggressively. This inaction persisted despite the Company’s ample liquidity, demonstrated by a low 2.2x GAAP Net Debt/EBITDA and an excessively high Liquidity Coverage Ratio of 3.1x Q2 and 3.2x in Q3 2025. This excess, non-earning cash was readily available for a highly accretive buyback. This failure to capture this valuation represented a significant opportunity cost. At an estimated intrinsic value of 8.0x–12.0x EV/EBITDA, a fully executed buyback would have generated an illustrative return of 215%–440%. This inaction resulted in substantial dilution: the Company had the potential to retire an estimated 7.5 million shares using the full authorization at discounted prices, but instead saw the outstanding share count increase by a net 3 million shares from Q1 to Q3 2025. This suggests the minimal buyback served primarily to offset insider equity issuance rather than return capital. Approximately $36 million of the $50 million program remains unused as of Q3 2025. This failure coincided with substantial increases in management’s unvested equity awards, demonstrating a misalignment between insiders and shareholders

DISCLAIMER: By including a shareholder resolution or management proposal in this database, neither the PRI nor the sponsor of the resolution or proposal is seeking authority to act as proxy for any shareholder; shareholders should vote their proxies in accordance with their own policies and requirements.

Any voting recommendations set forth in the descriptions of the resolutions and management proposals included in this database are made by the sponsors of those resolutions and proposals, and do not represent the views of the PRI.

Information on the shareholder resolutions, management proposals and votes in this database have been obtained from sources that are believed to be reliable, but the PRI does not represent that it is accurate, complete, or up-to-date, including information relating to resolutions and management proposals, other signatories’ vote pre-declarations (including voting rationales), or the current status of a resolution or proposal. You should consult companies’ proxy statements for complete information on all matters to be voted on at a meeting.